3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
16
Breast
13
Genitourinary
8
Thoracic
7
Head & Neck
4
CNS
4
Sarcoma
3
Gynecologic
2
Endocrine
2
Dermatologic
2
Tumor-Agnostic
1
NET
1
Conditions
Neuroendocrine Tumors
1
Interventions
lutetium Lu 177 dotatate
13
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
pembrolizumab
4
cabozantinib
4
Nivolumab
4
Octreotide
3
Lutetium-177
3
Ipilimumab
3
Everolimus
3
lenvatinib
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Temozolomide
2
Phantoms, Imaging
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
toripalimab
1
tislelizumab
1
telotristat ethyl
1
surufatinib
1
peposertib
1
pazopanib
1
pasireotide
1
entrectinib
1
copper dotatate CU-64
1
atezolizumab
1
abemaciclib
1
Surgical Procedures, Operative
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Surgical Procedures, Operative
×
NET
×
Clear all
NCT03012789
2024-04-30
NETest_Sx
Wren Laboratories LLC
Phase NA
Active not recruiting
40 enrolled